Fermenta Biotech Ltd · BSE:FERMENTA
Fermenta Biotech — Investor Presentation (July 2024)
31 slides from Fermenta Biotech's investor presentation, July 2024
Slide 1: Investor Presentation | July 2024
Investor Presentation | July 2024
Slide 2: Snapshot
Snapshot Top 3 Only manufacturer of Amongst top 3 manufacturers Global Presence in Vitamin D3 in India of Vitamin D3 globally 60+ countries Proprietary technology to 55+ Years of Vitamin D3 Both manufacturing facilities certified manufacture Vitamin D3 manufacturing experience by global regulatory b
Slide 3: Company Overview
Company Overview • Fermenta Biotech Limited (FBL) (Erstwhile DIL Ltd.) incorporated in 1951 by Dr. DVK Raju, is engaged in development and manufacturing of pharmaceuticals, biotechnology and Consolidated Revenue (INR Mn) & EBITDA Margins (%) environmental solutions used across various industries. 21
Slide 4: Board Of Directors
Board Of Directors Mr. Pradeep M. Chandan, Chairman, Non-Executive Independent Director Ms. Rajeshwari Datla, Non-Executive Director He has been appointed as an Independent Director w.e.f. February 12, 2024, and as the Chairman with effect from April 1, 2024. He is a She has around five decades of r
Slide 5: Board Of Directors
Board Of Directors Mr. Krishna Datla, Promoter & Executive Vice Chairman Mr. Prashant Nagre, Managing Director A Commerce Graduate from Mumbai University having around 20 Prashant Nagre is Managing Director of the company. Having spent years of experience in the industry three decades in the pharmac
Slide 6: Milestones
Milestones Leased land at Saykha for future expansion Launch of Vitamin AD2 Fermenta Biotech Ltd Enhanced Vitamin D3 --- for oil fortification Merger of DIL and FBL was --- Inaugurated established with its capacity at Dahej Establishment of Second plant for completed Developed and filed customized p
Slide 7: Geographical Presence
Geographical Presence Kullu Hamburg Delaware Nacogdoches Dahej, Saykha Thane Pennepalli, Geographical Revenue Mix % Andhra Pradesh (FY24) for Vit D3 and Other API ROW 26% R&D Centre and Registered Office India International Subsidiaries 44% Manufacturing Facility Delaware, USA: Fermenta Biotech USA
Slide 8: Manufacturing Plants
Manufacturing Plants Kullu (Himachal Pradesh) • Set up the Biotech plant in 1987 to manufacture Penicillin G Amidase and Acylase as well as CAL B enzymes. A new bulk drug division in 2004 to manufacture various APIs like Vitamin D3, Phenyramidol HCI and Silicon Powder. • Inaugurated customized premi
Slide 9: Accreditations & Certifications
Accreditations & Certifications* *Accreditations & Certifications are products / site specific Fermenta Biotech Limited 9
Slide 10: R&D and Quality
R&D and Quality R&D • Modern, fully equipped, DSIR approved Research & Development facility complemented by highly skilled and committed scientists. • Providing integrated solutions, processes and products for Biotech and Active Pharmaceutical Ingredients (API) • API R&D, combined with expertise on
Slide 11: Business Overview
BUSINESS OVERVIEW
Slide 12: About Vitamin D3
About Vitamin D3 For Humans • Vitamin D3 (Cholecalciferol) is a fat- • Vitamin D has been linked to a multitude of health benefits such as soluble vitamin, responsible for calcium general health and wellbeing, bone and mental health as well as absorption in the body. management and prevention of cer
Slide 13: FBL in Vitamin D3
FBL in Vitamin D3 CAGR Growth FY15 to FY24 Vitamin D3 Revenue (INR Mn) 14% • FBL is a leader in manufacturing Vitamin D3, and has 9% 27% 17% 18% the distinction of being the only organization in India 34% 56% to manufacture Vitamin D3 Volume Value 73% 83% 82% • The company has a Non-China dependent
Slide 14: Manufacturing Process and Applications
Manufacturing Process and Applications Backward Integrated Manufacturing Process Vitamin D3 Applications Sheep Wool Scouring of Wool For Humans Cleaned Wool Wool Grease Pharmaceuticals Dietary and Nutritional Supplements Food and Beverage Fortification Lanolin Cholesterol For Animals 7-Dehydrocholes
Slide 15: Integrated Biotechnology Capabilities
Integrated Biotechnology Capabilities Heritage of innovation in enzymes One-stop Destination for Green Chemistry FBL’s core expertise spans from microbial screening, fermentation, immobilization, biocatalysis, enzyme-mediated antibiotic synthesis to API intermediates & APIs Expertise One-stop destin
Slide 16: Other Segments
Other Segments APIs & Other intermediaries Environmental Solutions Fish Oil Cholesterol • For over 25 years, FBL is • FBL’s Environmental Solutions • As an extension to its product a trusted and reliable source provide unique advantages in portfolio, FBL has started of Phenyramidol HCl (muscle waste
Slide 17: Nutrition Portfolio
Nutrition Portfolio Nutritional Ingredients Fortified Rice Kernel • FBL sources Natural • FBL offers Fortified Rice Kernel (FRK) from its Astaxanthin for human and newly commissioned manufacturing facility in animal nutrition applications Andhra Pradesh. for the Indian subcontinent. Vitamins Customi
Slide 18: Nutraceutical Product Offerings
Nutraceutical Product Offerings Vitamin D3 and its various formats for Variants of Fat soluble vitamins Nutrition portfolio Pharmaceuticals Vitamin E Fortified Rice Kernel Dietary & Nutritional Supplements Food Vitamin K1 Natural Astaxanthin Feed Customized Premixes Veterinary Science Rodenticide Cu
Slide 19: Growth Drivers
Growth Drivers Internal Factors • Strong manufacturing capabilities with enhanced capacity utilizations to meet YoY production targets • Enhancing control and reduced dependence by backward integration World- Class • Sales footprint in 60+ countries spread across the globe Innovation Facilities in •
Slide 20: Strategic Initiatives
Strategic Initiatives Enhanced Focus Exiting of non-core business activities and laying long term emphasis on expanding the Nutraceutical business. Capital Allocation Plans All future capital allocation will be focused towards Nutrition business. Real Estate Business The company has taken steps towa
Slide 21: Industry Overview
INDUSTRY OVERVIEW
Slide 22: Vitamin D & Nutraceutical Industries & Drivers
Vitamin D & Nutraceutical Industries & Drivers VITAMIN D INDUSTRY • The Vitamin D market is estimated to account for about USD 1.25 billion in 2021 and is projected to reach a value of nearly USD 1.9 billion by 2027, growing at a CAGR of 7.1% from 2023 to 2027. • Vitamin D insufficiency affects almo
Slide 23: Vitamin D3 Animal Feed Price Trend
Vitamin D3 500 Animal Feed Price Trend 85 80 75 60 Price (Euro/kg) 33 32 30 25 22 20 20 16 13 12 9 10 8 8 7 8 7 6 6 6 7 7 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Q1 2024 Calendar Year Source: feedinfo.com Min of Low Max of High Fermenta Biotech Limited 23
Slide 24: Financial Overview
FINANCIAL OVERVIEW
Slide 25: Annual Standalone Financial Performance
Annual Standalone Financial Performance PARTICULARS (INR Mn) FY24 FY23 Y-o-Y Operational Revenue 3,071 3,289 (6.6)% Total Expenses 2,701 2,905 (7.0)% Operational EBITDA 370 384 (3.6)% Operational EBITDA Margins (%) 12.05% 11.68% 37% Other Income 82 85 (3.5)% Depreciation 237 245 (3.3)% Finance Cost
Slide 26: Historical Standalone Balance Sheet
Historical Standalone Balance Sheet PARTICULARS (INR Mn) FY24 FY23 FY22 PARTICULARS (INR Mn) FY24 FY23 FY22 Equity 3,142 3,360 3,959 Assets Non-current Assets 3,264 4,105 3,974 a) Equity share capital 144 144 144 a) Property, plant and equipment 2,364 2,048 1,935 b) Other equity 2,998 3,216 3,815 b)
Slide 27: Historical Consolidated Income Statement
Historical Consolidated Income Statement PARTICULARS (INR Mn) FY24 FY23 FY22 FY21 Operational Revenue 3,357 3,499 3,985 3,773 Total Expenses 3,082 3,323 3,371 2,956 Operational EBITDA 275 176 614 817 Operational EBITDA Margins (%) 8.19% 5.12% 15.41% 21.65% Other Income 118 86 81 82 Depreciation 247
Slide 28: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet PARTICULARS (INR Mn) FY24 FY23 FY22 PARTICULARS (INR Mn) FY24 FY23 FY22 Equity 2,851 3,126 3,714 Assets a) Equity share capital 144 144 144 Non-current Assets 3,061 3,835 3,928 a) Property, plant and equipment 2,364 2,048 1,935 b) Other equity 2,744 3,009 3,577
Slide 29: Historical Consolidated Financial Performance
Historical Consolidated Financial Performance Operational Revenue (INR Mn) Operational EBITDA (INR Mn) & Margins (%) PAT (INR Mn) & Margins (%) 25% 455 21.65% 3,985 817 12.06% 3,773 3,499 3,357 15.41% 20% 154 614 15% 3.86% 8.19% 275 FY21 FY22 FY23 FY24 10% -7.15% 5.12% 179 -240 5% -15.18% FY21 FY22
Slide 30: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d
Slide 31: Thank You
3 > a4 iS is) <= ke